Literature DB >> 19387481

Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.

Mark J Bluth1, Lisa C Zaba, Dariush Moussai, Mayte Suárez-Fariñas, Helen Kaporis, Linda Fan, Katherine C Pierson, Traci R White, Alexander Pitts-Kiefer, Judilyn Fuentes-Duculan, Emma Guttman-Yassky, James G Krueger, Michelle A Lowes, John A Carucci.   

Abstract

To determine the phenotype and function of myeloid dendritic cells (DCs) from human cutaneous squamous-cell carcinoma (SCC), we studied their surface marker expression and allo-stimulatory potential ex vivo. There were abundant CD11c(+) myeloid DCs, as well as TNF and inducible nitric oxide synthase (iNOS)-producing DCs, in and around SCC tumor nests. Although myeloid DCs from SCC, adjacent non-tumor-bearing skin, and normal skin, were phenotypically similar by flow cytometry, and there was a pronounced genomic signature of mature DCs in SCC, they showed different T-cell stimulatory potential in an allogeneic mixed leukocyte reaction. Myeloid DCs from SCC were less potent stimulators of allogeneic T-cell proliferation than DCs from non-tumor-bearing skin. Culture with a DC-maturing cytokine cocktail (IL-1beta, IL-6, TNF-alpha, and PGE(2)) enhanced stimulatory potential in DCs from non-tumor-bearing skin, whereas SCC-associated DCs remained poor stimulators of T-cell proliferation. The microenvironment associated with SCC showed expression of TGF-beta, IL-10, and VEGF-A, factors capable of suppressing the DC function. These findings indicate that CD11c(+)/HLA-DR(hi) DCs from SCC are mature, but are not potent stimulators of T-cell proliferation compared with phenotypically similar DCs isolated from non-tumor-bearing skin. Identification of mechanisms responsible for suppression of tumor-associated DCs may provide insight into the evasion of immunosurveillance by SCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387481      PMCID: PMC2846605          DOI: 10.1038/jid.2009.96

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  58 in total

1.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

2.  STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

3.  Nitric oxide regulates Th1 cell development through the inhibition of IL-12 synthesis by macrophages.

Authors:  F P Huang; W Niedbala; X Q Wei; D Xu; G J Feng; J H Robinson; C Lam; F Y Liew
Journal:  Eur J Immunol       Date:  1998-12       Impact factor: 5.532

4.  Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion.

Authors:  Arnold H Zea; Paulo C Rodriguez; Michael B Atkins; Claudia Hernandez; Sabina Signoretti; Jovanny Zabaleta; David McDermott; David Quiceno; Amanda Youmans; Anne O'Neill; James Mier; Augusto C Ochoa
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Oral immune tolerance mediated by suppressor T cells may be responsible for the poorer prognosis of foregut cancers.

Authors:  John Larkin; Mark Tangney; Chris Collins; Garrett Casey; Michael G O'Brien; Declan Soden; Gerald C O'Sullivan
Journal:  Med Hypotheses       Date:  2005-11-09       Impact factor: 1.538

Review 6.  Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Authors:  M R Young; D M Lathers
Journal:  Int J Immunopharmacol       Date:  1999-04

7.  Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm.

Authors:  Yasunori Ishibashi; Shigebumi Tanaka; Kohei Tajima; Takeshi Yoshida; Hiroyuki Kuwano
Journal:  Oncol Rep       Date:  2006-05       Impact factor: 3.906

8.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).

Authors:  Michelle A Lowes; Francesca Chamian; Maria Veronica Abello; Judilyn Fuentes-Duculan; Shao-Lee Lin; Rachel Nussbaum; Inna Novitskaya; Henrietta Carbonaro; Irma Cardinale; Toyoko Kikuchi; Patricia Gilleaudeau; Mary Sullivan-Whalen; Knut M Wittkowski; Kim Papp; Marvin Garovoy; Wolfgang Dummer; Ralph M Steinman; James G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-27       Impact factor: 11.205

9.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.

Authors:  K Steinbrink; H Jonuleit; G Müller; G Schuler; J Knop; A H Enk
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

10.  Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia.

Authors:  Asifa S Haider; Sara B Peters; Helen Kaporis; Irma Cardinale; Ji Fei; Jurg Ott; Miki Blumenberg; Ann M Bowcock; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2006-04       Impact factor: 8.551

View more
  34 in total

1.  Langerhans cells from human cutaneous squamous cell carcinoma induce strong type 1 immunity.

Authors:  Hideki Fujita; Mayte Suárez-Fariñas; Hiroshi Mitsui; Juana Gonzalez; Mark J Bluth; Shali Zhang; Diane Felsen; James G Krueger; John A Carucci
Journal:  J Invest Dermatol       Date:  2012-03-08       Impact factor: 8.551

2.  Nitric oxide controls an inflammatory-like Ly6C(hi)PDCA1+ DC subset that regulates Th1 immune responses.

Authors:  Daniela Giordano; Chang Li; Mehul S Suthar; Kevin E Draves; Daphne Y Ma; Michael Gale; Edward A Clark
Journal:  J Leukoc Biol       Date:  2010-12-22       Impact factor: 4.962

3.  Retrospective chart review of skin cancer presence in the wide excisions.

Authors:  Ye Yuan; Michelle L Duff; Dawn L Sammons; Shiyong Wu
Journal:  World J Clin Cases       Date:  2014-03-16       Impact factor: 1.337

4.  Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated.

Authors:  Julia S Pettersen; Judilyn Fuentes-Duculan; Mayte Suárez-Fariñas; Katherine C Pierson; Alexander Pitts-Kiefer; Linda Fan; Daniel A Belkin; Claire Q F Wang; Shivaprasad Bhuvanendran; Leanne M Johnson-Huang; Mark J Bluth; James G Krueger; Michelle A Lowes; John A Carucci
Journal:  J Invest Dermatol       Date:  2011-02-10       Impact factor: 8.551

5.  Skin cancer in transplant recipients, out of the woods. Scientific retreat of the ITSCC and SCOPE.

Authors:  O R Colegio; E M Billingsley
Journal:  Am J Transplant       Date:  2011-08       Impact factor: 8.086

Review 6.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

7.  Hedgehog/Gli1 signal pathway facilitates proliferation, invasion, and migration of cutaneous SCC through regulating VEGF.

Authors:  Qian Sun; Jing Bai; Renrong Lv
Journal:  Tumour Biol       Date:  2016-10-17

8.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

9.  Interleukin 6 regulates psoriasiform inflammation-associated thrombosis.

Authors:  Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward
Journal:  JCI Insight       Date:  2016-12-08

10.  Toll-like receptors: role in dermatological disease.

Authors:  Aswin Hari; Tracy L Flach; Yan Shi; P Régine Mydlarski
Journal:  Mediators Inflamm       Date:  2010-08-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.